Question 1

What is Tenax Therapeutics?

Accepted Answer

Tenax Therapeutics is a Company.

Question 2

How often does Tenax Therapeutics appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 12 articles.

Question 3

When was Tenax Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on Jul 02, 2026.

Question 4

When was Tenax Therapeutics last mentioned in news?

Accepted Answer

Last active on Aug 17, 2026.

Question 5

What is Tenax Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: -35 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Tenax Therapeutics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Tenax Therapeutics?

Accepted Answer

Tenax Therapeutics LEVEL Trial Presentation (Jul 02, 2026, 6 articles).

Question 8

How did the "Tenax Therapeutics LEVEL Trial Presentation" event impact Tenax Therapeutics?

Accepted Answer

Tenax Therapeutics announced that results from its Phase 3 LEVEL clinical trial will be presented at the European Society of Endocrinology Congress 2026. The company expects to report topline data in August 2026, which could significantly impact its stock price and future prospects for TNX-103 (oral levosimendan).

Question 9

How did the "Tenax Therapeutics Phase 3 Trial Failure" event impact Tenax Therapeutics?

Accepted Answer

Tenax Therapeutics is the central entity; its lead drug failed a pivotal trial, causing an 84-85% stock drop and triggering a securities investigation.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.